Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT: Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev, 2006, 12. vsk, nro 3–4, s. 178–207. PubMed:17227286doi:10.1111/j.1527-3458.2006.00178.x(englanniksi)
DeAnne Philipps: Wellbutrin®: Misuse and Abuse by Incarcerated Individuals. Journal of Addictions Nursing, February 2012, 23. vsk, nro 1, s. 65–69. PubMed:22468662doi:10.3109/10884602.2011.647838(englanniksi)
Baribeau, Danielle; Araki, Keyghobad Farid: Intravenous Bupropion: A Previously Undocumented Method of Abuse of a Commonly Prescribed Antidepressant Agent. Journal of Addiction Medicine, May–June 2013, 7. vsk, nro 3, s. 216–217. PubMed:23519045doi:10.1097/ADM.0b013e3182824863(englanniksi)
Terry P, Katz JL (1997). "Dopaminergic mediation of the discriminative stimulus effects of bupropion..". Psychopharmacology (Berl) 134 (2): 201–12. DOI:10.1007/s002130050443. PMID 9399385.
Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B (2003). "In vivo activity of bupropion at the human dopamine transporter..". Biol Psychiatry 54 (8): 800–5. DOI:10.1016/S0006-3223(02)01834-6. PMID 14550679.
Slemmer J E, Martin R M, Damaj M I (2000). "Bupropion is a Nicotinic Antagonist". J Pharmacol Exp Ther 295 (1): 321–327. PMID 10991997.
Fryer J D, Lukas R J (1999). "Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine". J Pharmacol Exp Ther 288 (6): 88–92. PMID 9862757.
Arias HR (2009). "Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?". Int. J. Biochem. Cell Biol. 41 (11): 2098–108. doi:10.1016/j.biocel.2009.05.015. PMID 19497387.
”Abuse potential of common psychiatric medications”, Substance abuse treatment for persons with HIV/AIDS, s. 83–4. Treatment Improvement Protocol. Rockville: Substance Abuse and Mental Health Services Administration. Teoksen verkkoversio.
Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT: Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev, 2006, 12. vsk, nro 3–4, s. 178–207. PubMed:17227286doi:10.1111/j.1527-3458.2006.00178.x(englanniksi)
DeAnne Philipps: Wellbutrin®: Misuse and Abuse by Incarcerated Individuals. Journal of Addictions Nursing, February 2012, 23. vsk, nro 1, s. 65–69. PubMed:22468662doi:10.3109/10884602.2011.647838(englanniksi)
Baribeau, Danielle; Araki, Keyghobad Farid: Intravenous Bupropion: A Previously Undocumented Method of Abuse of a Commonly Prescribed Antidepressant Agent. Journal of Addiction Medicine, May–June 2013, 7. vsk, nro 3, s. 216–217. PubMed:23519045doi:10.1097/ADM.0b013e3182824863(englanniksi)
